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Summary
Addition of fibronectin fragments (Fn-fs) to cultured cartilage explants has been shown to mediate extensive cartilage matrix degradation
followed by anabolic responses.
Objective: To determine whether specific Fn-fs regulate cartilage metabolism through a mechanism, in part, involving insulin-like growth
factor (IGF) and insulin-like growth factor binding proteins (IGFBPs).
Methods: Primary bovine articular chondrocyte cultures were treated with Fn-fs. mRNA from the cultures was analysed by Northern blotting.
Changes in the levels of IGFBPs in cellular extracts and conditioned media were analysed by Western ligand blotting. Explant cultures of
bovine articular cartilage were used to assay release of exogenous IGF-I and IGFBP-2. An analog of IGF-I with altered affinity for IGFBPs
was used to assay the effect of IGFBPs on proteoglycan synthesis.
Results: The Fn-fs increased protein levels of IGFBPs-2, -3 and -5 in conditioned media and of IGFBP-2 in cell extracts by as much as
nine-fold. Conversely, the protein level of constitutively expressed IGBP-4 was decreased in conditioned medium. Northern blot analysis
reflected increased IGFBP-3 mRNA but not decreased IGFBP-4 mRNA. The IGF-I analog was more effective at restoring PG synthesis
suppression by Fn-fs than was wild type IGF-I.
Conclusions: The Fn-fs increased levels of IGFBPs in cultures of bovine articular chondrocytes and elicited release of IGFBP-2 and IGF-I
from articular cartilage. The increased level of IGFBPs may trap IGF-I and account in part for the initial suppression of PG synthesis. Induced
proteinases may subsequently liberate IGF-I and cause greatly enhanced anabolic processes, contributing to cartilage repair. © 2002
OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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There are many observations of enhanced anabolic activi-
ties in early osteoarthritic cartilage as well as in explant
cultures of human cartilage. For example, cartilage from
donors with mild and moderate osteoarthritic (OA) shows
enhanced proteoglycan (PG) synthesis rates, while carti-
lage from donors with severe OA shows low PG synthesis
rates1. Further, osteoarthritic cartilage that shows initially
enhanced PG synthesis rates, later shows decreased syn-734thesis2. Little is known of how this anabolic response is
initiated. A thorough understanding of the mechanism for
this early attempted but failed repair response may allow
us to bolster its magnitude and allow completion of the
reparative program.
As a means of understanding attempted repair, we have
used a cartilage explant culture system in which matrix
damage is initiated by addition of 29-kDa amino-terminal or
140-kDa Arg-Gly-Asp containing, proteolytic fragments of
fibronectin (Fn-fs). These Fn-fs elevate synthesis of the
catabolic cytokines IL-1 and TNF-3,4 which in turn
cause increased expression of matrix metalloproteinases
(MMPs), including MMP-33,5–8 and aggrecanase-like activi-
ties9,10 resulting in PG degradation3–8,11,12. These Fn-fs at
high concentrations also temporarily suppress synthesis of
PG in cartilage tissue11,12. The PG synthesis suppression
is followed by a compensatory reparative response.
Mechanistically, this Fn-f activity requires penetration of
intact cartilage6 and probably involves the 51 fibronectin
receptor since analog peptides of the Arg-Gly-Asp integrin-
binding sequence block activities of both the 29-kDa and
140-kDa Fn-fs13. The physiological significance of these
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other Fn-fs, the 29-kDa and 140-kDa Fn-fs are found at
high levels in synovial fluids of patients with rheumatoid
arthritis and OA14 and that injection of Fn-fs into rabbit knee
joints causes severe and apparently irreversible loss of
articular cartilage PG within 7 days15.
One of the most interesting features of this model is that
as the concentration of Fn-fs is reduced, severe cartilage
matrix damage is no longer evident. Instead, PG synthesis
rates are immediately enhanced as well as steady state
levels of the PG content of the cartilage11. However, with
extended time in culture, the explants ultimately begin to
show depletion of PG content. Thus, at low concentrations
of Fn-fs the treated tissue behaves like early OA tissue as
shown by an anabolic response that precedes matrix
damage. Further, if cartilage is treated with high concen-
trations of Fn-f for a period of time too brief to allow severe
matrix damage, and the Fn-fs are removed, an anabolic
response is initiated16. The culturing conditions used to
initiate these anabolic responses have also been shown to
make the tissue more refractory to subsequent insults11,16.
Thus, the anabolic response–catabolic response observed
in human osteoarthritic cartilage can be mimicked in this
Fn-f treatment model.
We have proposed that this anabolic response is due to
IGF-I, a major PG synthesis-promoting factor in cartilage
tissue17. This was based on observations that Fn-f treat-
ment of cartilage enhances release of IGF-I into the
media4. When added to explant or monolayer cultures,
IGF-I can enhance synthesis of aggrecan, link protein, type
II collagen18 and hyaluronan19; it can also counter the
effects of IL-1 or TNF-20, two of the proinflammatory
cytokines associated with reduced anabolic processes and
increased catabolic processes, characteristic of OA21,22.
Our earlier work suggested that the ability of the Fn-f to
enhance IGF-I release is not due to up-regulation of IGF-I
message or protein synthesis since IGF-I protein release
was enhanced in the presence of metabolic inhibitors4. A
more likely possibility is that enhanced proteolysis of the
matrix enhanced release of IGF-I stored in the cartilage
tissue. We also considered that there may be a second
event, prior to proteolysis, that bolstered an IGF-I
response; Fn-fs might enhance synthesis of IGF-I binding
proteins (IGFBPs) that would trap IGF-I around the cells
and enhance the effect of IGF-I once the IGFBPs are
degraded. IGFBPs have properties that would support such
a role. IGFBPs belong to a family of six differentially
regulated proteins that bind IGFs specifically, with high
affinity and thereby alter the activity of IGFs. IGFBPs can
either potentiate or attenuate IGF-I activity, depending
upon the type of IGFBP and on the involvement of extra-
cellular matrix (ECM). The activities of the IGFBPs have
been reviewed23.
Our objectives were to investigate whether Fn-fs might
affect changes in the levels of IGFBPs expressed by
articular chondrocytes. We conclude that some of the
ability of Fn-fs to initially suppress PG synthesis and to later
enhance PG synthesis as observed in developing OA might
be due to increased IGFBPs.from the Nichols Institute (San Juan Capistrano, CA).
IGF-I and Des(1-3)-IGF-I were purchased from GroPep
(Adelaide, Australia). The IGF-I was a recombinant human
form. Additional IGF-I was purchased from Austral
Biologicals (San Ramon, CA). Antisera against IGFBPs
were purchased from Upstate Biotechnology, Inc. (Lake
Placid, NY). A 2.2 kb bovine IGFBP-3 cDNA was provided
by Dr Cheryl Conover (Mayo Clinic, Rochester, MN). A
505 bp human IGFBP-4 cDNA probe was provided by Dr
Shunichi Shimasaki (Dept. of Reproductive Medicine, Uni-
versity of California, San Diego). Statistical analysis was
performed by the unpaired two-way Student’s t-test where
P<0.05 was considered significant. For most analysis, N≥4.
Isolation of the Fn-fs from human plasma fibronectin (Fn)
was performed as described5. The two Fn-fs studied were
a well-defined thrombin-generated heparin and fibrin-
binding 29-kDa amino-terminal Fn-f, which is the most
active on cartilage tissue, and a mixture of carboxyl-
terminal Fn-fs of 100–140-kDa that contain the cell-binding
region and which we refer to as the 140-kDa Fn-f5.PREPARATION OF HIGH-DENSITY BOVINE ARTICULAR
CHONDROCYTE MONOLAYER CULTURES AND CARTILAGE EXPLANT
CULTURES
Bovine articular cartilage was removed from the meta-
carpophalangeal joints of adult bovine animals (18–20
months old) obtained from the slaughterhouse within 1–2 h
of death. Cartilage was washed twice with Hank’s balanced
salt solution (HBSS) that contained penicillin and strepto-
mycin. The cartilage was either cultured or chondrocytes
were released for monolayer culture. To release the bovine
articular chondrocytes (BAC), the cartilage was incubated
first in a solution of 0.4% pronase (Calbiochem Corp., La
Jolla, CA) w/v in DMEM with 5% fetal bovine serum for
90 min at 37°C under 5% CO2. The cartilage slices were
then washed three times with serum-free DMEM then
incubated under the same conditions in a solution of 0.02%
collagenase P (Roche Diagnostics Corp., Indianapolis, IN)
w/v in DMEM, 5% serum for 18 h. Following digestion, the
cells were washed in serum-free DMEM, counted using a
hemacytometer and seeded at densities of 5.0×105 or
7.5×105 cells/cm2 in 10% serum/DMEM. The medium was
changed every other day.LIGAND BLOT ANALYSIS OF IGFBPS
Cultured cells were washed twice with HBSS and then
adjusted to serum-free DMEM. One day later, Fn-fs were
added in fresh serum-free DMEM. After a 48-h incubation,
the media were collected and concentrated 10-fold; the
cells were extracted with non-reducing SDS sample
buffer24. Samples of cell extracts and concentrated media
containing 150 g protein were separated by electrophore-
sis through a 13% polyacrylamide gel24 and transferred to
a nitrocellulose membrane at 200 V for 2 h. The IGFBPs
were analysed by ligand blotting performed essentially as
described25. Briefly, the membranes were then rinsed in
TBS (0.05 M Tris, 150 mM NaCl, pH 7.4) containing 3%
NP-40, blocked with TBS, 0.1% Tween-20, 1% BSA for 2 h
and then incubated overnight with 2×105 cpm/ml 125I
labeled human recombinant IGF-I, prepared as described26
with a final specific activity of 295–305 Ci/g. Membranes
were then rinsed with TBS, 0.1% Tween-20 and finally withMaterials and methods
All common chemicals, except where noted, were pur-
chased from Sigma Chemical Co. (St Louis, MO). Sodium
35S-sulfate (43 Ci/mg S) was from ICN Biomedicals, Inc.
(Costa Mesa, CA). The IGF-I assay kits were purchased
736 C. R. Purple et al.: Fibronectin fragments upregulate IGF binding proteinsTBS. After drying, membranes were dried, autoradio-
graphed and the X-ray sheets analysed using a Storm
Phosphorimager and ImageQuant software (Molecular
Dynamics, Sunnyvale, CA). In initial ligand blot exper-
iments 100-fold excess unlabeled IGF-I was included as a
control for binding specificity. Binding was found to be
specific and these controls were discontinued (data not
shown).analysed by the method of Masuda et al.IMMUNOPRECIPITATION OF IGFBP-2 AND IGFBP-4
To form the immune complexes, rabbit anti-bovine
IGFBP-2 or rabbit antihuman IGFBP-4 (UBI, Lake Placid,
NY) was diluted 1:20 with Pansorbin (Calbiochem Corp., La
Jolla, CA) solution and incubated, with agitation, for 4 h at
4°C. The immune complexes were then washed four times
with TBS and then re-suspended in 0.5 ml of this buffer. A
100 l volume of the immune complexes was incubated for
18 h with pre-cleared conditioned media from Fn-f treated
BAC cultures. The immune complexes were then washed
with TBS. The Pansorbin suspension was then boiled in
SDS-PAGE sample buffer and the bound proteins analysed
by ligand blotting. As per the vendor (UBI): the antihuman
IGFBP-4 antiserum cross-reacts with the bovine protein
and there is approximately 50% cross-reactivity of the
IGFPB-4 antiserum with IGFBP-2 protein.NORTHERN BLOT ANALYSIS
Total RNA was extracted from monolayer cultures of
BAC with RNAzol B (Tel-Test, Inc., Friendswood, TX) using
the manufacturer’s protocol. However, to obtain sufficiently
pure RNA from BAC, re-extraction of the aqueous phase
was required. RNA (10 g per lane) was electrophoresed
through a 1% agarose formaldehyde gel and then trans-
ferred to uncharged nylon membrane (NEN, Inc., Boston,
MA). Membranes were probed with 2.2 kb bovine IGFBP-3
or with a 505 bp human IGFBP-4 cDNA probe. The probes
were labeled with alpha 32P-CTP using Random Primers
Kit (Gibco BRL, Inc., Rockville, MD). The membranes were
pre-hybridized overnight at 48°C in a solution of 5× NaCl,
sodium phosphate EDTA (SSPE), 50% deionized forma-
mide, 10% dextran sulfate, 5× Denhardt’s solution and 1%
and SDS. Following pre-hybridization, the membranes
were hybridized for 18 h at 50°C with 1×106 cpm/ml of
cDNA probe, then washed at 55°C sequentially with 2×
SSPE, 0.1% SDS, 1× SSPE, 0.1% SDS and 0.1× SSPE,
0.1% SDS. Autoradiography was performed at −70°C with
a Cronex intensifying screen and X-Omat film from Kodak.IMMUNOFLUORESCENT LOCALIZATION OF IGFBP-2
Cells were plated into eight-well chamber slides at low
density (25 000 cells/cm2) in 10% serum/DMEM adjusted
to 250 g/ml hyaluronidase. Cells were allowed to adhere
overnight and then the media replaced with 10% serum/
DMEM. After an additional 18 h, cells were rinsed five times
with HBSS and cultured in serum-free DMEM containing
100 nM 29-kDa Fn-f for 48 h. Cells were then rinsed with
PBS and fixed for 5 min with 1.5% paraformaldehyde in
PBS. The fixed cells were then incubated 1 h with 3% BSA
in PBS, followed by incubation for 1 h with a 1000-fold
dilution of rabbit antibovine IGFBP-2 antisera in 1% BSA/
PBS. The cells were rinsed with PBS and incubated for 1 h
with a 1000-fold dilution of a rhodamine conjugated goatantirabbit IgG. After rinsing with PBS, antibody labeling was
visualized by fluorescence microscopy.EFFECT OF DES (1-3) IGF-I AND IGF-I ON PG SYNTHESIS
To test the effect of mutant IGF-I, BAC in DMEM were
incubated 24 or 48 h with 100 nM Fn-f, followed by adjust-
ment of the media to 20 ng/ml of IGF-I or Des (1-3) IGF-I
(GroPep, Adelaide, Australia). After an additional 20 h of
incubation, the media were adjusted to 10 Ci of 35SO4 for
a 2-h pulse-chase labeling. The cells were then extracted
with 4 M guanidine HCl. The cell extracts were exhaustively
dialysed against H2O and 35SO4 incorporation was
27EFFECT OF ANTI-IGFBP-2 AND ANTI-IGFBP-4 ON PG SYNTHESIS
SUPPRESSION BY THE 29-KDA AND 140-KDA FN-FS
Polyclonal antisera against IGFBP-2 (UBI, Lake Placid,
NY) and IGFBP-4 (Austral Biologicals, San Ramon, CA),
with or without Fn-f, were incubated with monolayer cul-
tures in serum-free DMEM for 48 h. During the final 2 h the
cultures were labeled with 35SO4 as described above.
Sulfate incorporation was quantified using the method of
Masuda et al.27.FN-F MEDIATED RELEASE OF RHODAMINE LABELED HRIGFBP-2
AND HRIGF-I FROM CARTILAGE
Both IGFBP-2 and IGF-I were labeled using NHS-
rhodamine according to the manufacturer’s protocol
(Pierce Chem. Co., Rockford, IL), using quantities of 1 g
of IGFBP-2 and 10 g of IGF-I. Explant cultures of bovine
articular cartilage were incubated for 24 h with either
100 ng/ml IGF-I or 50 ng/ml IGFBP-2. The media were
removed and the tissue was rinsed twice with serum-free
DMEM and the media were replaced with either serum-free
DMEM or serum-free DMEM with 100 nM 29-kDa Fn-f.
Following a further 48-h incubation the tissue was rinsed
twice and prepared for cryosectioning. Fluorescence
was photographed on a Nikon microscope equipped with
epifluorescence.TESTS OF EFFECTS OF MMP-3 ON PG CONTENT, PG SYNTHESIS
AND IGF-I RELEASE
ProMMP-3 was isolated from chondrocyte monolayer
cultures treated with 100 nM Fn-f in serum-free DMEM as
described13. Activation of proMMP-3 was performed by
adjustment to 10 mM aminophenylmercuric acetate, fol-
lowed by exhaustive dialysis. MMP-3 was added to carti-
lage in DMEM to a final concentration of 5 g/ml. Cartilage
tissue was removed periodically to measure cartilage PG
content as well as measure rates of PG synthesis. Aliquots
of media were removed to measure IGF-I content.ASSAYS FOR IGF-I
To assay the Fn-f conditioned media, aliquots (0.5 ml) of
conditioned media were collected and, without freezing,
immediately dialysed against 10 mM NaCl, 10 mM Tris,
pH 7.4, and concentrated 10× on a Speed-O-Vac concen-
trator without application of heat. Assays were performed
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Osteoarthritis and Cartilage Vol. 10, No. 9 737using an RIA kit from the Nichols Institute (San Juan
Capistrano, CA) as directed by the manufacturer. This kit
recognizes bovine IGF-I as well as human IGF-I. Linear
equations for the standard curves had r2 values of greater
than 0.98. The data shown are the means and S.D. values of
at least three separate tissue culture wells. Day 0 time
points correspond to the amount of material found in the
media at the start of the experiment, immediately after
addition of the Fn-f. For kinetic points, the contents
reported correspond to accumulation up to the respective
time point.Results
THE FN-FS INCREASED IGFBPS
In addition to native Fn, two Fn-fs were tested, the
amino-terminal 29-kDa fragment and a cell binding 140-
kDa fragment. As shown in Fig. 1, addition of either of the
Fn-fs, or, to a lesser extent, native Fn, to cultured chondro-
cytes resulted in increased levels of several IGFBPs both in
the conditioned media and in the cell extracts as compared
with untreated cells. Densitometric data summarized in
Table I illustrate that the greatest effect of the Fn-fs was on
the 30-kDa IGFBP, which is probably IGFBP-5, based on its
molecular weight. The experiments summarized in Table I
are representative of three separate experiments. Con-
versely, the Fn-fs did not alter levels of a 24-kDa IGFBP in
the cell extracts but decreased its levels in the conditioned
media. The 24-kDa IGFBP was detected by the phoshorim-
ager during densitometric analysis; however the band is not
apparent in the photograph of the autoradiogram shown in
Fig. 1. Native Fn had weaker effects than the Fn-fs. The
assignments, as based on masses28 were: IGFBP-4 for the
24-kDa band, IGFBP-5 or glycosylated IGFBP-4 for the
30-kDa band, IGFBP-2 for the 32-kDa band and IGFBP-3
for the 38/42-kDa doublet. The ligand blot analysis shown
in Fig. 2 demonstrates that the effect of the Fn-fs on IGFBP
levels was greater at 1 M than 100 nM. While the magni-
tude of the increase of the 30-kDa protein was greater at
0.1 M, it was at the 1 M concentration that both the 30
and 32-kDa proteins were increased. There was a
detectable increase as low as 1 nM 29-kDa Fn-f (data not
shown).Fig. 1. Effect of Fn-fs on IGFBP activity as shown by ligand blot
analysis. Bovine articular chondrocytes in monolayer cultures were
cultured for 48 h in serum-free DMEM and the conditioned media
and cell extracts analysed by ligand blotting. Shown are cultures
with no addition (Con) or addition of 100 nM 29-kDa (29), 140-kDa
Fn-fs (140) or with 100 nM Fn (Fn). Markers on left show positions
of molecular weight standards.Table I
Summary of the effects of Fn-fs on changes in IGFBP levels in CM and SDS extracts of bovine articular
chondrocytes in serum free high-density monolayer cultures
Cell extracts Conditioned media
IGFBP Mr
29-kDa
Fn-f
140-kDa
Fn-f Fn
29-kDa
Fn-f
140-kDa
Fn-f Fn
39 2 3 1 4 2 1
34 3 4 1.3 5 2 2
32 5 5 2 4 2 2
30 9 9 4 4 2 3
24 1 1 1 0.6 0.6 0.8
Cells were cultured for 48 h with 100 nM 29-kDa Fn-f, 100 nM 140-kDa Fn-f or 100 nM fibronectin (Fn). The
concentrated media and the SDS extracts were analysed by ligand blotting and quantified by densitometry. The
changes in IGFBP levels are expressed as a fold increase of IGFBP under the experimental conditions, with
respect to the untreated control.HE IGFBPS ELEVATED BY THE FN-FS INCLUDED IGFBP-2 AS
HOWN BY IMMUNOPRECIPITATION
To simply identify the 24- and 32-kDa IGFBPs, con-
itioned media were immunoprecipitated, as described in
ethods, with antisera against IGFBP-2 or IGFBP-4; the
recipitated protein was analysed by ligand blotting. Figure
(left lane) shows that the 24-kDa band found in the
ultures and which was decreased in intensity in the
onditioned media by the 29-kDa Fn-f (Fig. 1) was
GFBP-4. However, since the IGFBP-4 antiserum has
bout 50% cross-reactivity with IGFBP-2 (Per UBI, Inc.),
ome 32/34-kDa IGFBP-2 was also detected in the anti-
GFBP-4 lane. As shown in the right lane, the precipitate
738 C. R. Purple et al.: Fibronectin fragments upregulate IGF binding proteinscontained 34-kDa IGFBP-2, one of the proteins
up-regulated by the 29-kDa Fn-f. Notably missing from the
IGFBP-4 precipitate is a band of glycosylated IGFBP-4 at
30-kDa, further suggesting that the 30-kDa IGFBP
increased by the Fn-fs is IGFBP-5.THE FN-FS INCREASED CELL BOUND IGFBP-2 AS SHOWN BY
IMMUNOFLUORESCENCE
To confirm the effect of Fn-fs on IGFBP-2 levels and to
determine sites of deposition, monolayer cultures treatedwith the 29-kDa Fn-f for 48 h in DMEM were reacted with
anti-IGFBP-2 followed by incubation with rhodamine
labeled antirabbit IgG and fluorescence microscopy. Figure
5 shows that IGFBP-2 was strongly increased by the Fn-f
and that the binding protein was found surrounding the
chondrocytes. These data are consistent with the data
above showing up-regulation of IGFBP-2 and the strong
presence of IGFBP-2 in the cell extracts. When similar
cultures were probed with anti-IGFBP-4, the Fn-f treated
cells showed only background fluorescence, at the level of
untreated cells (data not shown); confirming that IGFBP-4
was not localized around the chondrocytes.Fig. 2. Effect of varying Fn-f concentration on IGFBPs as shown by
ligand blot analysis. Cultures were established as described in Fig.
1. The ligand blot shows extracts of cells cultured with no Fn-f
(Control) or with 100 nM or 1 M 29-kDa Fn-f or 140-kDa Fn-f. The
positions of 30-kDA and 32-kDa are shown on the left.Fig. 3. Immunoprecipitation of IGFBP-2 and IGFBP-4 and visuali-
zation of IGFBPs by ligand blot analysis. Media conditioned by
culturing chondrocytes with 100 nM 29-kDa Fn-f were precipitated
with antisera against IGFBP-2 or -4 and the precipitates were
analysed by ligand blotting. The positions for IGFBP-4 and -2 are
shown on the left, respectively, at 24-kDa and 34-kDa.ANTISERA AGAINST THE 51 FN RECEPTOR ENHANCED IGFBP
LEVELS AND SUPPRESSED PG SYNTHESIS
Since other properties of the Fn-fs such as MMP-3
release were affected by antibodies to this Fn receptor
(unpublished data), we tested the effect of rabbit antihuman
51 antiserum first on IGFBP levels and then on PG
synthesis. PG synthesis was tested because suppression
of PG synthesis is a significant activity of the Fn-fs11,12.THE FN-FS INCREASED IGFBP-3 MRNA, BUT HAD NO EFFECT ON
IGFBP-4 MRNA
Since no antibodies were available against bovine
IGFBP-3, the effect of Fn-fs on IGFBP-3 was confirmed by
Northern blot analysis. IGFBP-4 mRNA was also analysed
since the effects of the Fn-fs decreased the level of this
protein in the previous experiments. As shown in top panel
of Fig. 4, the IGFBP-4 cDNA hybridized to a 2.2 kb mRNA,
consistent with the published size of the bovine IGFBP-4
mRNA29. Densitometric scanning and normalization of
IGFBP-4 mRNA to 18s rRNA indicated that there was no
significant difference between the Fn-f treated cultures and
the untreated control, based on N=3. The cDNA probe for
bovine IGFBP-3 (Fig. 4, bottom panel), hybridized to a
single 1.6 kb mRNA. This size corresponds to the size
reported for IGFBP-330. Normalization of the IGFBP-3
mRNA to 18s rRNA showed a 2.3 fold increase in IGFBP-3
mRNA.
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antihuman 51 for 48 h resulted in up-regulation of the 32
and 30-kDa IGFBPs, which were probably IGFBP-2 and -5,
respectively (panel A), as well as dose-dependent suppres-
sion of PG synthesis (panel B). Antigoat IgG dilutions had
no effect on either activity. Therefore, the Fn-f effects on
IGFBPs may be occurring through this receptor.IGF-I ALSO ENHANCED IGFBP LEVELS
Since the Fn-fs enhance release of IGF-I and IGF-I is
known to elevate IGFBPs, we tested the effect of IGF-I in
this system. Figure 7 shows that within 48 h, 50 ng/ml IGF-I
(I) increased levels of IGFBPs in the cell extract (CE), of
30-, 32- and 34-kDa bands that are probably IGFBPs-4, -5
and -2, respectively. The corresponding conditioned media
(CM) show in the treated cells the additional presence of an
intense 24-kDa band, which is probably IGFBP-4, and light
bands of 34- and 42-kDa, which probably correspond toIGFBPs-2 and one of the bands of the IGFBP-3 doublet.
This is consistent with the observation that IGF-I can
induce IGFBPs31. However, comparison with Fig. 1 shows
that a major difference between the Fn-f and IGF-I effects is
that Fn-fs decreased IGFBP-4, while it was increased by
IGF-I.Fig. 4. Effect of Fn-fs on IGFBP-4 and IGFBP-3 mRNA levels.
Chondrocytes were cultured for 48 h without Fn-f (C) or with
100 nM 29-kDa or 140-kDa Fn-fs. Total RNA was analysed with an
IGFBP-4 (top panel) or an IGFBP-3 cDNA probe (bottom panel).
The autoradiogram of the Northern blot is shown in top part of each
panel and the ethidium bromide stained 18s rRNA is shown in the
lower part.Fig. 5. Effect of Fn-fs on cellular bound IGFBP-2 epitopes. Bovine
articular chondrocytes were cultured in chamber slides for 48 h,
with or without 100 nM 29-kDa Fn-f in serum-free DMEM. Cells
were fixed with 1.5% paraformaldehyde in PBS, then incubated
with antisera against IGFBP-2 and finally with rhodamine-labeled
antirabbit IgG secondary antibody. Binding was visualized by UV
fluorescence microscopy. The left panels are phase contrast of
−Fn-f and +Fn-f, while the right panels are the corresponding
fluorescent images. The final magnification was 150×.THE EFFECT OF FN-F ENHANCED IGFBP LEVELS WAS TO
SUPPRESS PG SYNTHESIS AS SHOWN BY USE OF IGF-I MUTANTS
To address the role of the IGFBPs in 29-kDa Fn-f
mediated PG synthesis suppression, we asked whether the
truncated IGF-I analog, des (1-3) IGF-I was more or less
effective at reversing PG synthesis suppression that wild
type IGF-I. Des (1-3) IGF-I binds to the type I IGF-I receptor
with the same affinity as IGF-I, but des (1-3) IGF-I has
greatly reduced affinity for the IGFBPs32. Monolayer cul-
tures were first incubated for either 48 or 72 h with the
29-kDa Fn-f, then either the des(1-3) IGF-I or IGF-I was
added for an additional 24 h. Finally, sulfate incorporation
into the cell layer was assayed.
Figure 8, panel A, shows that the 48-h incubation with
the 29-kDa Fn-f suppressed PG synthesis to 20% of control
levels (P≤0.01), while addition of IGF-I (20 ng/ml final) or
Des (1-3) IGF-I (20 ng/ml final) during the last 24 h of
culture restored PG synthesis to approximately 50%
(P≤0.01) of the untreated control level. Since, as shown in
panel B, 20 ng/ml of either factor should have increased
PG synthesis to nearly four-fold of control untreated cells,
this suggests that a component(s), probably IGFBPs,
up-regulated by the Fn-fs, is offsetting the effects of the
growth factors on PG synthesis. Surprisingly, the Des IGF-I
did not reverse the effect of the Fn-f more than did IGF-I.
However, in cultures incubated for 72 h with the 29-kDa
Fn-f and with the growth factors (panel C), IGF-I restored
PG synthesis to the level of the control (P≥0.05) (controls
shown in Panels B and D), while the des (1-3) IGF-I
elevated the PG synthesis to 140% of control (P≤0.05).
Thus, with the longer incubation, the 29-kDa Fn-f induced
factors, probably IGFBPs, that suppress PG synthesis and
which can be effectively counteracted by IGF-I. Even more
740 C. R. Purple et al.: Fibronectin fragments upregulate IGF binding proteinseffective in reversing PG synthesis suppression was des
(1-3) IGF-I with its reduced affinity for IGFBPs and there-
fore greater availability to the IGF-I receptor. Panel D
shows the effects of the growth factors incubated in the last
24 h in the 72-h cultures.THE EFFECT OF FN-F ENHANCED IGFBP LEVELS WAS TO
SUPPRESS PG SYNTHESIS AS SHOWN BY USE OF ANTISERA
AGAINST IGFBPS
To provide confirmatory data for the role of IGFBPs in PG
synthesis suppression, antisera against IGFBP-2 and -4
were tested for their effects on PG synthesis by monolayer
cultures incubated for 48 h with 100 nM 29-kDa [Fig. 9(A)]
or 140-kDa Fn-f [Fig. 9(B)] with or without the antisera.Anti-IGFBP-2 was tested because IGFBP-2 is one of the
major IGFBPs up-regulated by the Fn-f and found in the cell
extracts. Anti-IGFBP-4 was tested because the data to this
point had suggested that it did not have a major role in Fn-f
mediated activities and, in fact, it was not up-regulated at
the mRNA level.
As shown in Fig. 9(A), the 29-kDa Fn-f significantly
suppressed PG synthesis, while the IGFBP-2 antiserum
alone increased PG synthesis 63% above control levels
(P≤0.01). The IGFBP-2 antiserum that was added to the
cultures 24 h prior to the addition of the 29-kDa Fn-f
significantly reversed or blocked the PG synthesis suppres-
sion caused by the 29-kDa Fn-f (P≤0.05). Therefore, a role
for IGFBP-2 in Fn-f mediated PG synthesis suppression is
suggested. In contrast, the IGFBP-4 antiserum alone did
not enhance PG synthesis, nor did the IGFBP-4 antiserum
block the effect of the Fn-f on suppressing PG synthesis
[Fig. 9(A)]. Neither IGFBP-2 nor IGFBP-4 antisera had a
significant effect on PG synthesis suppression by the
140-kDa Fn-f [Fig. 9(B)].Fig. 6. Effect of anti-51 antiserum on IGFBP levels and PG
synthesis. Chondrocytes were cultured for 48 h with anti-51
antiserum or an irrelevant antigoat IgG antiserum. Panel A: cell
extracts were analysed for IGFBPs by ligand blotting. Shown are
untreated control (left), antigoat IgG (middle) and anti Fn receptor
(51) (right). The positions for 32-kDa and 30-kDa IGFBPs (top to
bottom) are shown in the margin on left. Panel B: newly synthe-
sized PG was labeled with a two-hour pulse of 35SO4 in cultures
treated with increasing concentrations of antibody. Sulfate incor-
poration was quantified using the alcian blue binding assay. Cell
extracts and media were assayed and added to reflect total
labeled PG.Fig. 7. Effect of IGF-I on IGFBP expression. Chondrocytes were
cultured for 48 h with IGF-I in serum-free DMEM. Cell extracts
(CE) (left panel) and conditioned media (CM) (right panel) were
analysed by ligand blotting. Each panel shows cell extracts from
control cells (C) and IGF-I (I) treated cells. The locations of 24-kDa,
30-kDa and 32-kDa molecular weight standards are shown on left.THE 29-KDA FN-F ENHANCED RELEASE OF IGFBP-2 AND IGF-I
FROM CULTURED CARTILAGE AS SHOWN BY FLUORESCENCE
MICROSCOPY
Since IGF-I and IGFBP-2 can accumulate in the cartilage
matrix, we investigated whether the Fn-f could cause
release of exogenous rhodamine labeled IGF-I or IGFBP-2.
Rhodamine labeled IGFBP-2 was incubated for 24 h with
Osteoarthritis and Cartilage Vol. 10, No. 9 741bovine cartilage explants in serum-free DMEM and the
media were replaced with serum-free DMEM with or with-
out 100 nM 29-kDa Fn-f. After 48 h, 15 sections from three
different explants were examined. Figure 10 shows that
addition of labeled IGFBP-2 resulted in enhanced fluor-
escence around the cells and that Fn-f treatment enhanced
release of the labeled IGFBP-2. Figure 11 shows that under
similar conditions, when rhodamine labeled IGF-I was
added to cartilage for 24 h, followed by addition of Fn-f,
there was also an initial accumulation around chondrocytes
and that Fn-f treatment decreased the labeled IGF-I in the
tissue.MMP-3 AND TRYPSIN ALSO FIRST SUPPRESSED PG SYNTHESIS,
THEN ALLOWED INCREASES TO SUPERNORMAL RATES WHILE IGF-I
RELEASE WAS ENHANCED
Since it is known that proteolysis of binding proteins can
liberate IGF-I, we tested whether MMP-3 alone could mimic
the action of the Fn-f. Figure 12 shows that adjustment of
cartilage cultures to 5 g/ml MMP-3 in DMEM led to a
reduction of PG content as well as an initial suppression of
PG synthesis. However, after the MMP-3 was removed, PG
synthesis rates increased to above normal levels. This was
associated with enhanced release of IGF-I into the media.
However, this anabolic response was insufficient to restore
PG content by day 9.Fig. 8. Effect of IGF-I and Des (1-3) IGF-I on PG synthesis by BAC
treated for 48 or 72 h with Fn-fs. (A) BAC were incubated for 24 h
with 100 nM 29-kDa Fn-f. IGF-I or Des(1-3) IGF-I was added to a
final concentration of 20 ng/ml and the cultures were incubated for
a further 24 h. During the final 4 h of each incubation 10 Ci of
35SO4 were added. (C) Same as (A) except the Fn-f treatment was
48 h with the growth factors added for the final 24 h. Total
incubation was 72 h. Panels B and D show control incubations with
growth factor alone for 48 and 72 hours, respectively.Discussion
Our objective was to test the hypothesis that Fn-fs might,
in part, regulate PG synthesis through a mechanism involv-
ing IGF-I and IGFBPs. The hypothesis was based on our
observations that the Fn-fs suppress PG synthesis11,12 and
enhance release of IGF-I and catabolic cytokines from
explant cultures of human articular cartilage4. Since both
IGF-I32 and catabolic cytokines regulate IGFBPs33, it was
also of interest to test for induced IGFBPs in our Fn-f
model. An additional rationale was that this Fn-f model
expresses certain characteristics of OA chondrocytes and
IGF-I and IGFBPs are enhanced in OA34; in situ hybridiz-
ation35 and immunohistochemical36 studies have shown
that IGF-I mRNA and protein are increased in chondrocytes
that surround osteoarthritic lesions. The increased expres-
sion of IGF-I protein was found to be proportional to the
severity of the lesion36. Paradoxically, cultured osteo-
arthritic chondrocytes are resistant to the effects of IGF-I37–
39. Although there is no evidence of damage to or reduction
in the number of IGF-I receptors on osteoarthritic chondro-
cytes, osteoarthritic cartilage shows increased binding sites
for IGF-I39,40. Thus, it has been proposed that the
enhanced number binding sites in osteoarthritic cartilage is
due to enhanced levels of IGFBPs. Bhakta et al. have
demonstrated that IGFs bind the cartilage matrix indirectly
through IGFBPs41.
To investigate the effects of Fn-fs on IGFBPs, both
conditioned media and cell extracts of monolayer cultures
were analysed. Serum-free monolayer cultures were
studied rather than explant cultures, because this system
allowed us more easily to isolate RNA and the serum-free
culture conditions eliminated IGF-I and IGFBPs contained
in serum. However, the use of serum-free monolayer cul-
tures did not allow us to study long-term cultures or
long-term kinetics of expression. Data obtained from
monolayer cultures of chondrocytes are valuable for under-
standing the response of chondrocytes to stimuli, however,
care must be taken in the extrapolation of the data to
cartilage; the matrix of the monolayer is not the same as
cartilage. Nonetheless, we have shown that MMP-3 and
other MMPs are up-regulated not only in explant cul-
tures3,6,7, but also in monolayer cultures8. We also know
that PG synthesis suppression occurs in explant cul-
tures11,12,16 and as shown here, in monolayer cultures as
well. Thus, extrapolation of our results to explant cultures
may have some validity, although we would not expect that
the activities of the Fn-fs would be of the same magnitude
in both culture systems.
We had to use a combination of methods to identify the
IGFBPs, since ligand blot analysis only provided masses of
IGFBPs, not their exact identities. Another parameter was
the choice of Fn-fs. In order to ensure that our conclusions
would reflect Fn-fs in general, we tested two distinct types
of Fn-fs, a 29-kDa amino-terminal Fn-f and a central
140-kDa Fn-f. The amino-terminal Fn-f is the most potent5
but does not bind to Fn receptors through the Arg-Asp-Ser-
Gly recognition sequence, while the 140-kDa Fn-f is less
potent5 but does bind directly to Fn receptors through this
sequence. Although these Fn-fs are dissimilar, both types
suppress PG synthesis12, elevate MMPs3,5–8 and cause
cartilage matrix degradation3. We have recently shown
that the activities of both types of Fn-fs also can be
suppressed by antisense oligonucleotides to the 5 subunit(Osteoarthritis Cart, in press). Therefore, our conclusions
here probably represent activities of Fn-fs in general.
742 C. R. Purple et al.: Fibronectin fragments upregulate IGF binding proteinsFig. 9. Effect of IGFBP-2 or -4 antiserum on PG synthesis by BAC. Chondrocytes were incubated for 24 h with a 1:1000 dilution of
anti-IGFBP-2 or IGFBP-4 antiserum before the addition of 100 nM 29-kDa Fn-f. The cells were incubated for an additional 48 h with Fn-f
and/or antisera. Newly synthesized PG was labeled with a 2-h pulse of 35SO4 and incorporation quantified.Fig. 10. Effect of Fn-fs on association of rhodamine labeled
IGFBP-2 with cartilage. Rhodamine labeled IGFBP-2 was incu-
bated for 24 h with cartilage tissue. The IGFBP-2 media were
removed and replaced with either SF DMEM (-Fn-f) or with SF
DMEM+100 nM 29-kDa Fn-f (+Fn-f). The explant cultures were
incubated for a further 48 h with these media. The tissues were
rinsed and prepared for frozen sectioning. The phase contrast
micrographs on the left were taken with an automatic exposure
while the fluorescent micrographs on the right were exposed for
30 s. Images are representative of 30 sections examined.Fig. 11. Effect of Fn-fs on association of rhodamine labeled IGF-I
with cartilage. Bovine articular cartilage explant cultures were
incubated for 24 h with 100 nM rhodamine labeled IGF-I. The IGF-I
medium was replaced with either serum free DMEM (-Fn-f) or the
same with 100 nM 29-kDa Fn-f (+Fn-f) and the cultures incubated
for a further 48 h. The tissue was rinsed and prepared for frozen
sectioning. The phase contrast micrographs on the left were taken
with an automatic exposure while the fluorescent micrographs on
the right were exposed for 30 s. Images presented are represen-
tative of 15 sections examined. Final magnification for these was
50×.We found that the Fn-fs increased levels of IGFBPs of
24-kDa to 42-kDa, corresponding to IGF-2, -3 and -5 as
shown by ligand blot analysis. IGFBPs-2 and -4 were
identified by immunoprecipitation followed by ligand blot-
ting. Because specific antisera against bovine IGFBP-3
were not commercially available, the identity of the 43/39-
kDa doublet as IGFBP-3 was inferred from its molecular
weights and from Northern blot analysis that confirmedenhanced levels of IGFBP-3 mRNA. The presence of these
IGFBPs in bovine chondrocyte cultures is consistent with
the work of Olney et al.31 that showed IGFBP-2, -3, and -4
in cultures of BAC. It was interesting that an antibody
against the 51 Fn receptor also increased IGFBPs.
Induction by this antibody suggests that the effect of the
Fn-fs on IGFBPs may be mediated through the Fn receptor.
The observation that the Fn-fs enhanced levels of
IGFBP-2 and -3 can be compared to a report that in
osteoarthritic synovial fluid only IGFBP-3 is elevated, while
in rheumatoid arthritic synovial fluid, BPs -2 and -4 are
elevated in addition to BP-337. While the Fn-fs increased
Osteoarthritis and Cartilage Vol. 10, No. 9 743Fig. 12. Effect of MMP-3 and trypsin on PG content, PG synthesis
rate and IGF-I release from cartilage explants into the media.
Bovine articular cartilage in serum-free DMEM was incubated with
5 g/ml MMP-3 for days 0–6. The media were then removed and
replaced with 10% serum/DMEM. Panel A shows the PG content
during the culture. Curves are control cartilage (C) and MMP-3
treated cartilage (h). Panel B shows the PG synthesis rates.
Curves are control cartilage (C) and MMP-3 treated cartilage (h).
Panel B shows the IGF-I released into the media after correcting
for the serum contribution beyond day 6. Curves are control
cartilage (C) and MMP-3 treated cartilage (h).IGFBPs -2, -3 and -5, they decreased the level of IGFBP-4.
As shown by ligand and Northern blotting respectively,
IGFBP-4 protein was decreased while the level of IGFBP-4
mRNA remained unchanged. The decrease in IGFBP-4
protein may have been a result of increased proteolysis
induced by the Fn-fs. Proteolysis is a well-documented
mechanism of post-translational regulation of IGFBP
activity; serine proteases as well as MMPs can degrade
IGFBPs to non-IGF-I binding fragments42–45. Such serine
proteases have been identified in several different types of
cells42,46–48. Additionally, a kallikrein-like serine protease
that cleaves IGFBP-5 into low-mass non-IGF-I binding
fragments has been identified36. Since IGFBP-4 has can
be degraded by serine proteinases39, it is possible that a
serine proteinase activity might also be involved in Fn-f
effects on cartilage tissue. Interestingly, IGF-I itself may
partly regulate degradation of IGFBPs since binding ofIGF-I by IGFBP-5 has been shown to stabilize this IGFBP
against proteolysis by a specific IGFBP-5 protease42.
The effect of the up-regulated IGFBPs on chondrocyte
metabolism must be discussed in relation to the reported
dualistic activities of the IGFBPs. IGFBPs can both block
and enhance the activity of IGF-I. In this context, the role of
the extracellular matrix in regulating the IGF-I binding
activity of IGFBPs also must be considered. For example,
while soluble IGFBPs can attenuate the activity of IGF-I,
IGFBPs associated with the cell surface PGs or matrix PGs
can potentiate the effect of IGF-I49. Perhaps this can be
explained by observations that the interaction with the
matrix may facilitate dissociation of IGF-I from complexes
with IGFBPs. For example, binding of the IGFBP-2/IGF-I
complex to chondroitin-6-sulfate reduces the affinity of
IGFBP-2 for IGF-I 3-fold50. In addition, other extracellular
matrix components that bind IGFBPs, such as heparin,
heparan sulfate or dermatan sulfate can also reduce the
affinity of IGFBP-3 or -5 for IGF-I51. This regulation by the
matrix can also be explained by observations that PGs
slow degradation of IGFBP-5 by an IGFBP-5 specific
protease52.
Based on the above observations, it is likely that at least
some IGFBPs serve to enhance delivery of IGF-I to
chondrocytes. Within the cartilage tissue, de novo synthe-
sized IGFBPs may serve to trap de novo synthesized IGF-I
and to sequester it as an inactive complex until needed and
until activated through protease activity. Current work is
directed toward testing for enhanced degradation of
IGFBPs in the Fn-f treated cultures.
One of the rationales for investigating whether Fn-fs
induce IGFBPs was based on observations that IGF-I
release is elevated in conditioned media of Fn-f treated
cartilage4 and that IGF-I enhances IGFBP levels53,54. For
example, in FRTL-5 cells, IGF-I enhances IGFBP-5 in the
conditioned media with a corresponding increase in
IGFBP-5 mRNA54. However, when we tested IGF-I on
BAC, it produced a different IGFBP profile than did Fn-fs. In
contrast to the Fn-fs, IGF-I increased IGFBP-4. Thus, the
Fn-f effects on IGFBPs cannot be explained solely through
effects on enhancement of IGF-I activity. Similarly, the
suppression of PG synthesis by Fn-fs is unlikely to occur
solely through modulation of the IGF/IGFBP axis.
The availability of IGF-I analogs that bind with normal
affinity to the type I IGF-I receptor, but have negligible
affinities for the IGFBPs32 allowed us to test the effect of
the up-regulated IGFBPs on IGF response of Fn-f treated
cells. The IGF-I analogue des (1-3) IGF-I was more active
in restoring PG synthesis following treatment with the
29-kDa Fn-f than was IGF-I. This result, coupled with our
observation that the PG synthesis was partially restored
following treatment of 29-kDa Fn-f cultured cells with the
IGFBP-2 antiserum, suggests that the overall effect of the
increased levels of the IGFBPs in this system is initially to
suppress PG synthesis. These data are consistent with our
observations that Fn-fs added to cartilage results in im-
mediate suppression of PG synthesis12 and suggest that
IGFBPs may play a role in this effect. The inability to cause
full restoration may suggest that another pathway, such as
catabolic cytokines, also contribute to PG synthesis sup-
pression. Since catabolic cytokines can also mediate PG
synthesis suppression by Fn-fs3,4, it is possible that both
cytokines and IGFBPs may be involved in PG synthesis
suppression, although they may not be effective at the
same time. It would be of interest to determine how much of
the suppressive role that has been assigned to catabolic
cytokines could occur through IGFBPs. However, since
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